HS
ACAD icon

HighVista Strategies’s Acadia Pharmaceuticals ACAD Stock Holding History

HighVista Strategies’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,287
Closed -$389K – 138
2024
Q3 		$389K Sell
25,287
-591
-2% -$9.86K 0.13% 139
2024
Q2 		$421K Buy
+25,878
New +$418K 0.15% 120
2023
Q4 		– Sell
-18,172
Closed -$379K – 127
2023
Q3 		$379K Sell
18,172
-10,619
-37% -$288K 0.18% 126
2023
Q2 		$690K Sell
28,791
-26,783
-48% -$595K 0.32% 92
2023
Q1 		$1.05M Sell
55,574
-1,044
-2% -$19.9K 0.85% 35
2022
Q4 		$901K Buy
56,618
+3,300
+6% +$51.6K 0.54% 51
2022
Q3 		$872K Buy
53,318
+13,418
+34% +$217K 0.5% 49
2022
Q2 		$562K Buy
39,900
+5,784
+17% +$108K 0.34% 71
2022
Q1 		$826K Buy
+34,116
New +$826K 0.53% 55
2021
Q2 		– Sell
-16,590
Closed -$428K – 117
2021
Q1 		$428K Buy
16,590
+2,246
+16% +$98.9K 0.32% 73
2020
Q4 		$767K Buy
14,344
+1,915
+15% +$95.1K 0.49% 49
2020
Q3 		$513K Buy
12,429
+3,635
+41% +$157K 0.37% 47
2020
Q2 		$426K Buy
+8,794
New +$422K 0.35% 44

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

HighVista Strategies's ACAD Position: Q4 2024 in Review

HighVista Strategies sold out of Acadia Pharmaceuticals (ACAD) in Q4 2024, closing a stake of 25,287 shares — an estimated $389K sold.

HighVista Strategies first reported a position in ACAD in Q2 2020 and held it in 13 quarters. The position peaked at $1.05M in Q1 2023. 296 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

  • HighVista Strategies reported no remaining Acadia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • HighVista Strategies sold 25,287 Acadia Pharmaceuticals shares in Q4 2024, an estimated $389K.
  • HighVista Strategies first reported a position in Acadia Pharmaceuticals in Q2 2020 and held it in 13 quarters.
  • HighVista Strategies's Acadia Pharmaceuticals position peaked at $1.05M in Q1 2023.
  • 296 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on HighVista Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.